PUBLISHER: The Business Research Company | PRODUCT CODE: 1763102
PUBLISHER: The Business Research Company | PRODUCT CODE: 1763102
Trasylol, the brand name for aprotinin, is a medication used to reduce bleeding and the need for transfusions during major surgeries, such as heart surgery. It works by inhibiting enzymes that break down blood clots, but it has been under scrutiny due to potential risks, including kidney dysfunction.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The primary types of trasylol (aprotinin) are natural aprotinin and recombinant aprotinin. Natural aprotinin is a protein extracted from bovine lungs, used to prevent excessive bleeding during surgery by inhibiting the breakdown of blood clots. It is distributed through hospital pharmacies, retail pharmacies, and online platforms for various medical procedures, including cardiac surgeries, orthopedic surgeries, and others.
The trasylol (aprotinin) market research report is one of a series of new reports from The Business Research Company that provides trasylol (aprotinin) market statistics, including trasylol (aprotinin) industry global market size, regional shares, competitors with a trasylol (aprotinin) market share, detailed trasylol (aprotinin) market segments, market trends and opportunities, and any further data you may need to thrive in the trasylol (aprotinin) industry. This trasylol (aprotinin) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry
The trasylol (aprotinin) market size is expected to see strong growth in the next few years. It will grow to $3,24,920 million in 2029 at a compound annual growth rate (CAGR) of 9%. The growth in the forecast period can be attributed to the rising prevalence of cardiovascular diseases, growing focus on advanced medical treatments, rising availability of genetic and diagnostic tests, rising prevalence of chronic disease, and increasing number of surgical procedures. Major trends in the forecast period include the adoption of high-end medical technologies and pharmaceuticals, the integration of tranexamic acid in clinical guidelines, the adoption of antifibrinolytic drugs in developing markets, emerging applications in sports medicine, and a focus on patient safety and personalized medicine.
The increasing number of surgical procedures is expected to drive the growth of the trasylol (aprotinin) market. The rise in chronic lifestyle diseases has led to more advancements in medical technology, making surgeries more effective and accessible. As a result, the demand for surgical procedures is on the rise. Trasylol, a protease inhibitor, was historically used during surgeries like coronary artery bypass grafting (CABG) to reduce blood loss and minimize the need for blood transfusions. For example, in December 2023, the UK Health Security Agency reported an increase in CABG surgeries, with 27,524 surgeries conducted in 2023. This growing volume of surgical procedures is likely to boost the demand for trasylol.
The growing incidence of bleeding disorders is key factor contributing to the growth of the trasylol market. Bleeding disorders, which impair the blood's ability to clot properly, can result in excessive bleeding. This rise can be attributed to factors such as improved diagnosis, increased awareness, and genetic and aging factors. Trasylol (aprotinin) is commonly used in surgical settings to prevent excessive blood loss in high-risk surgeries, such as cardiac surgery, by inhibiting fibrinolysis and stabilizing blood clots. In October 2022, the World Federation of Hemophilia reported 427,685 global cases of bleeding disorders, including hemophilia and von Willebrand disease. This growing incidence of bleeding disorders is expected to drive demand for Trasylol (aprotinin).
A key trend in the trasylol market is the exploration of inhaled aprotinin as a potential treatment for SARS-CoV-2 infections. This research focuses on repurposing aprotinin as a protease inhibitor in the treatment of COVID-19 when administered via inhalation. For example, in April 2022, Kent University in the UK and Goethe University in Germany partnered to study the use of aprotinin in treating COVID-19. Their research demonstrated that aprotinin could inhibit viral entry, and clinical trials showed positive outcomes, including reduced hospital stays. This collaboration underscores the potential for repurposing existing treatments like Trasylol for emerging health crises, which could expand the market further.
Key player operating in the trasylol (aprotinin) market is Bayer AG
North America was the largest region in the trasylol (aprotinin) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in trasylol (aprotinin) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the trasylol (aprotinin) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The trasylol market consists of sales of products including tranexamic acid, aminocaproic acid, generic aprotinin injections, and desmopressin. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Trasylol (Aprotinin) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on trasylol (aprotinin) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for trasylol (aprotinin) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The trasylol (aprotinin) market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.